Poor
Not Aligned
Patient Risk:
Moderate
Summary
The provided AI content primarily addresses semaglutide missed-dose instructions and nonspecific effects, but is not evaluated against the supplied Ozempic label content for the specific topic 'RISK OF THYROID C-CELL TUMORS'. The included label-assessment block appears to support the thyroid C-cell tumor claim, but the main list of semaglutide dose-miss statements is not supported or contradicted by the supplied thyroid-cancer-focused label excerpts.
Category Scores
Accurate Statements
Ozempic label includes/addresses risk of thyroid C-cell tumors in rodents and states human relevance is unknown (supported).
5.1; 13.1; 17; 6
Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2 (reinforcing the thyroid C-cell tumor risk).
4; 5.1
Unsupported Statements
If a once-weekly semaglutide dose is missed, take it as soon as the patient remembers as long as it is within 5 days of the missed dose.
Not supported by the supplied Ozempic label excerpts (which focus on thyroid C-cell tumor risk).
After taking a missed semaglutide dose within 5 days, resume the regular semaglutide schedule with the next dose on the usual day.
Not supported by the supplied Ozempic label excerpts.
Patients should not double up semaglutide doses or take two doses at once to make up for a missed dose.
Not supported by the supplied Ozempic label excerpts.
Taking two semaglutide doses at once increases the risk of side effects such as nausea or low blood sugar.
Not supported by the supplied Ozempic label excerpts.
If more than 5 days have passed since the scheduled semaglutide dose, the missed dose should be skipped entirely.
Not supported by the supplied Ozempic label excerpts.
Taking semaglutide late does not improve blood sugar control enough to justify the added nausea or vomiting risk.
Not supported by the supplied Ozempic label excerpts.
Taking semaglutide late does not improve weight loss enough to justify the added nausea or vomiting risk.
Not supported by the supplied Ozempic label excerpts.
A single missed semaglutide dose typically causes minimal impact on overall blood sugar control/weight loss.
Not supported by the supplied Ozempic label excerpts.
Missing multiple semaglutide doses in a row can lead to temporary increases in A1C.
Not supported by the supplied Ozempic label excerpts.
Missing multiple semaglutide doses in a row can lead to stalled weight loss.
Not supported by the supplied Ozempic label excerpts.
When restarting semaglutide after a miss, nausea, diarrhea, or stomach pain may return more strongly as the body readjusts.
Not supported by the supplied Ozempic label excerpts.
Restarting semaglutide after a miss may increase risk of GI side effects such as nausea.
Not supported by the supplied Ozempic label excerpts.
Contacting a doctor after missing multiple semaglutide doses may result in restarting at a lower dose to minimize GI side effects.
Not supported by the supplied Ozempic label excerpts.
Contacting a doctor after missing multiple semaglutide doses may result in switching medications.
Not supported by the supplied Ozempic label excerpts.
Abrupt stopping of semaglutide after several misses can sometimes cause rebound hyperglycemia in diabetes patients.
Not supported by the supplied Ozempic label excerpts.
Contradictions
Important Omissions
Boxed warning text and/or explicit counseling elements for thyroid C-cell tumor risk (beyond 'supported' label-assessment).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Dose-miss instructions and several safety/efficacy effect statements are not supported by the provided thyroid C-cell tumor label excerpts, so label-accuracy for those instructions cannot be verified from the supplied content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Major portion of the AI-generated content provides missed-dose timing, safety, and outcome statements that are not supported or addressed by the supplied Ozempic label excerpts (focused on thyroid C-cell tumor risk).
Suggested Improvement
Limit claims to the provided on-label thyroid C-cell tumor risk information (5.1/13.1/4/6/17) or supply and evaluate the relevant Ozempic sections for missed-dose/dosing instructions.